Roche has entered into a definitive agreement to acquire select parts of the LumiraDx group, related to LumiraDx’s innovative point-of-care technology. Following closing of the transaction, which is expected by mid-2024, the acquired entities will be fully integrated into Roche Diagnostics.
LumiraDx’s technology integrates multiple point-of-care (POC) tests on a simple-to-use single instrument and brings more affordable and accessible testing to patients worldwide. The transformative POC solution will complement Roche’s centralised diagnostics portfolio across clinical chemistry, immunochemistry, coagulation and molecular, and across multiple disease areas.
“The addition of the LumiraDx technology to our diagnostics portfolio will enable us to transform testing at the point of care.” said Matt Sause, CEO Roche Diagnostics. “LumiraDx has developed a highly versatile platform that delivers strong performance across multiple disease areas and technologies. We believe this will enable better patient access to timely results in decentralised healthcare settings worldwide.”
Veronique Ameye, Chief Executive Officer of LumiraDx added: “Since our founding, we have sought to transform community-based healthcare by consolidating multiple point-of-care tests on a single instrument. We are thrilled that Roche will continue this important work and increase its reach around the globe. This will enable more patients to get fast and easy access to better diagnostic testing.”
The transaction is part of Roche’s vision to enable more patient-centric healthcare, with POC solutions that span the entire patient journey - from the home, pharmacy and general practitioner’s office to the emergency room, intensive care unit and beyond. The acquired technology platform offers a wide range of immunoassay and clinical chemistry tests, with great potential for additional high medical value tests in the future. These are capable of being stored at room temperature which enables convenient handling in a range of decentralised healthcare settings. By leveraging its extensive global reach and established affiliate network, Roche will be able to drive access to timely, accurate diagnostic results when and where patients need them most.
The transaction is subject to certain conditions including antitrust and regulatory approvals.
Under the terms of the agreement, at the closing of the transaction Roche will pay a purchase price of US$ 295 million (subject to customary closing adjustments) and an additional payment of up to US$ 55 million for the reimbursement of amounts to fund the POC technology platform business until the closing of this acquisition. The transaction is part of a pre-packaged UK administration sale, with the full support of LumiraDx group’s senior secured lender.
